360iResearch Logo
Global Cancer Immunotherapy Market
Report Code: MRR-C794A75 | Publishing Date: May 2020 | Number of Pages: 204
Global Cancer Immunotherapy Market | Market Research Report | Cumulative Impact of COVID-19

Market Segmentation & Coverage:

The research report categorizes the Cancer Immunotherapy Market to forecast the revenues and analyze the trends in each of the following segments:

On the basis of Function, the Cancer Immunotherapy Market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer.

On the basis of Product, the Cancer Immunotherapy Market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines further studied across Prophylactic Vaccines and Therapeutic Vaccines.

On the basis of End User, the Cancer Immunotherapy Market is studied across Cancer Research Institutes, Clinics, and Hospitals.

On the basis of Geography, the Cancer Immunotherapy Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The Cancer Immunotherapy Market is highly competitive and characterized by the presence of a large number of international and regional players in the market. The market has witnessed increasing competition between vendors based on the pricing model, technology differentiation, brand name, quality of service, price differentiation, and technical expertise.

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Immunotherapy Market including Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Janssen Global Services, LLC, Merck, Novartis, Pfizer, Seattle Genetics, Inc., and Spectrum Pharmaceuticals, Inc..

Scope of the Report:

AttributeDetails
Base Year for Estimation2019
Historical Period2017 - 2018
Estimation Period2020 - 2021
Forecast Year2025
Market RepresentationRevenue in USD Million
Report CoverageRevenue Forecast, Company Share, Competitive Landscape, and Industry Trends.
Customization ScopeIf you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization. We offer 20% free customization which is equivalent to 5 analysts working days.

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of the Cancer Immunotherapy Market. Moreover, the study highlights current market trends and provides forecast. We also have highlighted future trends in the Cancer Immunotherapy Market that will impact the demand during the forecast period. Moreover, the competitive analysis of the Cancer Immunotherapy Market brings an insight on the company usability profiles of the leading players. Additionally, the analysis highlights business overview, strategy, and SWOT analysis of the key companies in the market.

Reasons to Buy:

The Cancer Immunotherapy Market research study reveals hidden insights and dynamic, which in turn helps the players in the ecosystem take better strategic decisions. The firms looking for purchasing the Cancer Immunotherapy Market research report could look for following prospects on their way to better understand the market that can aid further decision making and possibly identify the best opportunities to exploit.

  • Evaluate the qualitative and quantitative aspects of the report and analyze the Cancer Immunotherapy Market penetration with respect to industries and geographies.
  • Evaluates the key vendors and deeply analyze competitive landscape, revenue pockets, market trends, growth prospects, pain points, drivers, restraints, challenges and opportunities of the Cancer Immunotherapy Market.
  • Evaluate the key vendors in the Cancer Immunotherapy Market in terms of products satisfaction and business strategy. This helps identify consumer preferences and understand its current position in 360iResearch FPNV Positioning Matrix.
  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & Coverage
    3. Years Considered for the Study
    4. Currency & Pricing
    5. Language
    6. Stakeholders
  2. Research Methodology
    1. Research Process
      1. Define: Research Objective
      2. Determine: Research Design
      3. Prepare: Research Instrument
      4. Collect: Data Source
      5. Analyze: Data Interpretation
      6. Formulate: Data Verification
      7. Publish: Research Report
    2. Research Execution
      1. Initiation: Research Process
      2. Planning: Develop Research Plan
      3. Execution: Conduct Research
      4. Verification: Finding & Analysis
      5. Publication: Research Report
    3. Research Outcome
      1. 360iResearch Market Share Analysis
      2. 360iResearch Competitive Strategic Window
  3. Executive Summary
    1. Market Outlook
    2. Function Outlook
    3. Product Outlook
    4. End User Outlook
    5. Geography Outlook
    6. Competitor Outlook
  4. Market Overview
    1. Introduction
    2. Cancer Immunotherapy Market, By Geography
  5. Market Dynamics
    1. Introduction
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
  6. Market Insights
    1. Porters Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    2. Cumulative Impact of COVID-19
    3. Client Customizations
  7. Global Cancer Immunotherapy Market, By Function
    1. Introduction
    2. Breast Cancer
    3. Colorectal Cancer
    4. Head & Neck Cancer
    5. Lung Cancer
    6. Melanoma
    7. Multiple Myeloma
    8. Prostate Cancer
  8. Global Cancer Immunotherapy Market, By Product
    1. Introduction
    2. Cell Therapies
      1. Chimeric Antigen Receptor T Cell Therapy
      2. Dendritic Cells
    3. Checkpoint Inhibitors
      1. Cytotoxic T-Lymphocyte-Associated Protein-4
      2. Programmed Death 1 & Programmed Death Ligand 1
    4. Immunomodulators
      1. Granulocyte-Macrophage Colony-Stimulating Factor
      2. Interferons
      3. Interleukins
      4. Oncolytic Virus
    5. Monoclonal Antibodies
      1. Bispecific Monoclonal Antibodies
      2. Conjugated Monoclonal Antibodies
      3. Naked Monoclonal Antibodies
    6. Vaccines
      1. Prophylactic Vaccines
      2. Therapeutic Vaccines
  9. Global Cancer Immunotherapy Market, By End User
    1. Introduction
    2. Cancer Research Institutes
    3. Clinics
    4. Hospitals
  10. Americas Cancer Immunotherapy Market
    1. Introduction
    2. Argentina
    3. Brazil
    4. Canada
    5. Mexico
    6. United States
  11. Asia-Pacific Cancer Immunotherapy Market
    1. Introduction
    2. Australia
    3. China
    4. India
    5. Indonesia
    6. Japan
    7. Malaysia
    8. Philippines
    9. South Korea
    10. Thailand
  12. Europe, Middle East & Africa Cancer Immunotherapy Market
    1. Introduction
    2. France
    3. Germany
    4. Italy
    5. Netherlands
    6. Qatar
    7. Russia
    8. Saudi Arabia
    9. South Africa
    10. Spain
    11. United Arab Emirates
    12. United Kingdom
  13. Competitive Landscape
    1. 360iResearch FPNV Positioning Matrix
      1. Quadrants
      2. Business Strategy
      3. Product Satisfaction
    2. 360iResearch Market Ranking Analysis
    3. 360iResearch Market Share Analysis
    4. Competitive Scenario
      1. Merger & Acquisition
      2. Agreement, Collaboration & Partnership
      3. New Product Launch & Enhancement
      4. Investment & Funding
  14. Company Usability Profiles
    1. Amgen Inc.
    2. Astrazeneca
    3. Bayer AG
    4. Bristol-Myers Squibb
    5. Celgene Corporation
    6. ELI Lilly and Company
    7. F. Hoffmann-La Roche Ltd
    8. GlaxoSmithKline Plc
    9. Janssen Global Services, LLC
    10. Merck
    11. Novartis
    12. Pfizer
    13. Seattle Genetics, Inc.
    14. Spectrum Pharmaceuticals, Inc.
  15. Appendix
    1. Discussion Guide
    2. Edition Details
    3. License Details
    4. Pricing Details

List of Tables

  1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2025 (USD MILLION)
  2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  34. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  35. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  36. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  37. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  38. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  39. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  40. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  41. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  42. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  43. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  44. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  45. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  46. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  47. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  48. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  49. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  50. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  51. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  52. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  53. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  54. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  55. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  56. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  57. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  58. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  59. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  60. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  61. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  62. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  63. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  64. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  65. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  66. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  67. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  68. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  69. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  70. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  71. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  72. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  73. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  74. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  75. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  76. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  77. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  78. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  79. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  80. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  81. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  82. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  83. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  85. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  86. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  87. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  88. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  89. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  90. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  91. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  92. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  93. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  94. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  95. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  96. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  97. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  98. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  99. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  100. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  101. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  102. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  103. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  104. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  105. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  106. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  107. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  108. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  109. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  110. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  111. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  112. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  113. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  114. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  115. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  116. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  117. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  118. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017-2025 (USD MILLION)
  119. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  120. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  121. GLOBAL CANCER IMMUNOTHERAPY MARKET: SCORES
  122. GLOBAL CANCER IMMUNOTHERAPY MARKET: BUSINESS STRATEGY
  123. GLOBAL CANCER IMMUNOTHERAPY MARKET: PRODUCT SATISFACTION
  124. GLOBAL CANCER IMMUNOTHERAPY MARKET: RANKING
  125. GLOBAL CANCER IMMUNOTHERAPY MARKET: MERGER & ACQUISITION
  126. GLOBAL CANCER IMMUNOTHERAPY MARKET: AGREEMENT, COLLABORATION & PARTNERSHIP
  127. GLOBAL CANCER IMMUNOTHERAPY MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  128. GLOBAL CANCER IMMUNOTHERAPY MARKET: INVESTMENT & FUNDING
  129. GLOBAL CANCER IMMUNOTHERAPY MARKET: EDITION DETAILS
  130. GLOBAL CANCER IMMUNOTHERAPY MARKET: LICENSE DETAILS
  131. GLOBAL CANCER IMMUNOTHERAPY MARKET: PRICING DETAILS

List of Figures

  1. GLOBAL CANCER IMMUNOTHERAPY MARKET: RESEARCH PROCESS
  2. GLOBAL CANCER IMMUNOTHERAPY MARKET: RESEARCH EXECUTION
  3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2019 VS 2025 (USD MILLION)
  4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2019 VS 2025 (USD MILLION)
  5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2019 VS 2025 (USD MILLION)
  6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2019 VS 2025 (USD MILLION)
  7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  8. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TYPE
  9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2025 (USD MILLION)
  10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  12. GLOBAL CANCER IMMUNOTHERAPY MARKET: MARKET DYNAMICS
  13. GLOBAL CANCER IMMUNOTHERAPY MARKET: PORTERS FIVE FORCES ANALYSIS
  14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2019 VS 2025 (USD MILLION)
  15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2025 (USD MILLION)
  16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2019 VS 2025 (USD MILLION)
  17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2025 (USD MILLION)
  18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2019 VS 2025 (USD MILLION)
  19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 (USD MILLION)
  20. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  21. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  22. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  23. GLOBAL CANCER IMMUNOTHERAPY MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
  1. Amgen Inc.
  2. Astrazeneca
  3. Bayer AG
  4. Bristol-Myers Squibb
  5. Celgene Corporation
  6. ELI Lilly and Company
  7. F. Hoffmann-La Roche Ltd
  8. GlaxoSmithKline Plc
  9. Janssen Global Services, LLC
  10. Merck
  11. Novartis
  12. Pfizer
  13. Seattle Genetics, Inc.
  14. Spectrum Pharmaceuticals, Inc.